Osteoporosis and Polypharmacy;Osteoporose und Polypharmazie

Zeitschrift fur Gerontologie und Geriatrie

Volumn 45, Issue 6, 2012, Pages 450-454

  Gosch, M ^a   Jeske, M ^b   Kammerlander, C ^c   Roth, T ^c  

^a Abteilung fur Innere Medizin und Akutgeriatrie   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c Universitatsklinik fur Chirurgie Innsbruck   (Austria)

Author keywords

Drug interactions; Fracture risk Elderly; Osteoporosis; Polypharmacy

Indexed keywords

BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; DRUG INTERACTION; DRUG TOXICITY; FEMALE; FRAGILITY FRACTURE; HUMAN; INCIDENCE; MALE; OSTEOPOROSIS; POLYPHARMACY; RISK ASSESSMENT; RISK FACTOR;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DRUG INTERACTIONS; DRUG TOXICITY; FEMALE; HUMANS; INCIDENCE; MALE; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; POLYPHARMACY; RISK ASSESSMENT; RISK FACTORS;

EID: 84865719296     PISSN: 09486704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00391-012-0374-7     Document Type: Article

References (52)

1. Leung F, Blauth M, Bavonratanavech S (2010) Surgery for fracture-streamlining the process. Osteoporos Int 21(Suppl 4):519-552
2. Bartl R (2008) Osteoporose - Prävention - Diagnostik - Therapie. Georg Thieme, Stuttgart-New York, pp 1-2
3. Becker C, Gebhard F, Muche R et al (1999) Epidemiologie der Stürze Älterer. Z Orthop 137:482-485
4. Häussler B, Gothe H, Göl D et al (2007) Epidemiology, treatment and costs of osteoporosis in Germany-the BoneEVA Study. Osteoporos Int 18:77-84
5. Kammerlander C, Gosch M, Kammerlander-Knauer U et al (2011) Long-term functional outcome in geriatric hip fracture patients. Arch Orthop Trauma Surg 131:1435-1444
6. Jennings LA, Auerbach AD, Maselli J et al (2010) Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc 58:650-657
7. Kuijpers MA, Marum RJ van, Egberts AC et al (2008) Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol 65:130-133
8. Gosch M, Roth T, Kammerlander C et al (2011) Treatment of osteoporosis in postmenopausal hip fracture patients after geriatric rehabilitation: changes over the last decade. Z Gerontol Geriatr 44:381-386
9. Solomon DH, Brookhart MA, Tsao P et al (2011) Predictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction rule. Osteoporos Int 22:1737-1743
10. Kirigaya D, Nakayama T, Ishizaki T et al (2011) Management and treatment of osteoporosis in patients receiving long-term glucocorticoid treatment: current status of adeherence to clinical guidelines and related factors. Intern Med 50:2793-2800
11. Reid IR, Heap SW (1990) Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med 150:2545-2548
12. Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of cortisteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777-787
13. Rejnmark L, Vestergaard P, Heickendorff L et al (2006) Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res 21:163-170
14. Heidrich FE, Stergachis A, Gross KM (1991) Diuretic drug use and the risk for hip fracture. Ann Intern Med 115:1-6
15. Lim LS, Fink HA, Blackwell T et al (2009) Loop diuretic use and rates of hip bone loss and risk of falls and fractures in older women. J Am Geriatr Soc 57:855-862
16. Verdel BM, Souverein PC, Egberts TC et al (2010) Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone 47:604-609
17. Haney EM, Chan BK, Diem SJ et al (2007) Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 167:1246-1251
18. Richards JB, Papaioannou A, Adachi JD et al (2007) Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 167:188-194
19. Haney EM, Warden SJ, Bliziotes MM (2010) Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone 46:13-17
20. Gajic-Veljanoski O, Bayoumi AM, Tomlinson G et al (2012) Vitamin K supplementation for the primary prevention of osteoporotic fractures: is it cost-effective and is future research warranted? Osteoporos Int (Epub ahead of print)
21. Philip WJ, Martin JC, Richardson JM et al (1995) Decreased axial and peripheral bone density in patients taking long-term warfarin. QJM 88:635-640
22. Gage BF, Birman-Deych E, Radford MJ et al (2006) Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 166:241-246
23. Barbour LA, Kick SD, Steiner JF et al (1994) A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 170:862-869
24. Dahlman TC (1993) Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 168:1265-1270
25. Pettilä V, Leinonen P, Markkola A et al (2002) Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 87:182-186
26. Ross FP (2006) M-CSF, c-Fms, and signaling in osteoclasts and their precursors. Ann N Y Acad Sci 1068:110-116
27. Leese GP, Jung RT, Guthrie C et al (1992) Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol (Oxf) 37:500-503
28. Faber J, Galløe AM (1994) Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 130:350-356
29. O'Connell MB, Madden DM, Murray AM et al (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118:778-781
30. Serfaty-Lacrosniere C, Wood RJ, Voytko D et al (1995) Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 14:364-368
31. Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947-2953
32. Laine L (2009) Proton pump inhibitors and bone fractures? Am J Gastroenterol 104(Suppl 2):21-26
33. Gray SL, LaCroix AZ, Larson J et al (2010). Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 170:765-771
34. Zaidi M (1990) Modularity of osteoclast behaviour and "mode-specific" inhibition of osteoclast function. Biosci Rep 10:547-556
35. Heikkinen S, Auwerx J, Argmann CA (2007) PPARgamma in human and mouse physiology. Biochim Biophys Acta 1771:999-1013
36. Grey A (2008) Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 19:129-137
37. Kahn SE, Zinman B, Lachin JM et al (2008) Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31:845-851
38. Motola D, Piccinni C, Biagi C et al (2012) Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. Drug Saf 35:315-323
39. Meier C, Kraenzlin ME, Bodmer M et al (2008) Use of thiazolidinediones and fracture risk. Arch Intern Med 168:820-825
40. Eastell R, Hannon RA, Cuzick J et al (2006) Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21:1215-1223
41. Howell A (2005) Adjuvant aromatase inhibitors for breast cancer. Lancet 366:431-433
42. Bartl R, Bartl C, Gradinger R (2009) Drug-induced osteopathies. Drugs, pathogenesis, forms, diagnosis, prevention and therapy. Orthopade 38:1245-1260
43. Vestergaard P, Hermann P, Jensen JE et al (2012) Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS). Osteoporos Int 23:1255-1265
44. Gosch M (2003) Are statins of value in therapy of osteoporosis? Wien Med Wochenschr 153:255-257
45. LaCroix AZ, Cauley JA, Pettinger M et al (2003) Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med 139:97-104
46. LaCroix AZ, Ott SM, Ichikawa L et al (2000) Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 133:516-526
47. Graham S, Hammond-Jones D, Gamie Z et al (2008) The effect of beta-blockers on bone metabolism as potential drugs under investigation for osteoporosis and fracture healing. Expert Opin Investig Drugs 17:1281-1299
48. Togari A, Arai M, Kondo A (2005) The role of the sympathetic nervous system in controlling bone metabolism. Expert Opin Ther Targets 9:931-940
49. Pasco JA, Henry MJ, Sanders KM et al (2004) Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 19:19-24
50. Laroche ML, Charmes JP, Nouaille Y et al (2007) Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol 63:177-186
51. Mannesse CK, Derkx FH, Ridder MA de et al (2000) Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing 29:35-39
52. Woolcott JC, Richardson KJ, Wiens MO et al (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169:1952-1960. (Review. Erratum in: Arch Intern Med 2010 170:477)